Feltl reiterated a “strong buy” rating for Heska (NASDAQ:HSKA) and raised its price target to $97 from $67 on an increased valuation multiple reflecting Heska’s improved positioning. The stock was quoted at $76.46 near midday on Jan. 26.Read More
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Lorin Jeffry Randall to its board and chairman of the audit committee.Read More
Analysts at Stifel and BTIG initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with “buy” ratings and price targets of $18 and $20, respectively. The stock closed at $13.80 on Friday.
“Obalon appears poised for dramatic top-line growth with its highly-differentiated intragastric balloon system, already FDA-approved to treat 30-to-40 body mass index range obese patients,” writes Rick Wise of Stifel.Read More
The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine.
The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from overdoses every day.Read More
Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director.
Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of pharmaceuticals. He has been serving as lead independent director of Galectin.Read More